Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Next-Gen RNA-Based Liquid Biopsy Platform Detects Multiple Cancer Types at Earliest Stages

By LabMedica International staff writers
Posted on 08 Jun 2023

A novel RNA- and AI-based platform has demonstrated the ability to detect multiple cancer types at the earliest stages using a single, standard blood sample. More...

The universal platform developed by Exai Bio (Palo Alto, CA, USA) has diverse applications across numerous cancer care scenarios, including screening, early detection, monitoring, molecular residual disease analysis, and therapy selection. The platform employs RNA sequencing to distinguish a new class of small, non-coding RNAs linked to cancer, known as orphan non-coding RNAs (oncRNAs). The RNA composition of the transcriptome delivers a more dynamic and exhaustive perspective of actionable cancer biology than the DNA content of the genome. The abundance of oncRNAs in the blood of cancer patients and their relative scarcity in those without cancer makes oncRNA-based tests remarkably sensitive and specific.

Exai has identified hundreds of thousands of unique oncRNAs through studies involving over 16,000 patients, creating a vast catalog that paves the way for developing innovative RNA-based tests for early cancer detection. Exai utilizes artificial intelligence (AI) and machine learning (ML) to analyze the multitude of oncRNAs found in cancer patients' blood by identifying distinct, cancer-specific patterns. Exai has proven that these oncRNA patterns can be used to detect various types and subtypes of cancer, predict the original tissue of cancer, and identify cancer in its earliest stages.

In Exai’s multi-cancer early detection (MCED) study, eight types of cancer - lung, stomach, pancreas, kidney, colorectal, breast, prostate, and the bladder - were analyzed, reflecting the majority of the societal cancer burden. The study showed successful detection of stage I breast and prostate cancers, both of which have been extremely difficult to identify at early stages using other blood-based methods. When a cancer signal was identified in the test group, Exai's platform was able to pinpoint the origin tissue with 88% accuracy for the top predicted cancer type and 95% accuracy considering the top two predictions, demonstrating the power of its unique generative AI technology. This new MCED data lend further support to the increasing evidence that Exai's platform is versatile, and capable of application across numerous tumor types and clinical uses, all through the use of standard blood samples.

“These results demonstrate that Exai’s RNA- and AI-based platform can detect stage I cancer at very high sensitivity across multiple cancers while also maintaining the high specificity which is required for real-world clinical utility,” said Patrick Arensdorf, chief executive officer of Exai Bio. “Exai is developing blood tests that have both high accuracy and cancer biology insights to improve cancer care.”

Related Links:
Exai Bio


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PlGF Test
Quidel Triage PlGF Test
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.